Plasma Mannose Levels Are Associated with Incident Type 2 Diabetes and Cardiovascular Disease

Cell Metabolism

Volumn 26, Issue 2, 2017, Pages 281-283

  Mardinoglu, Adil ^a,b   Stančáková, Alena ^c   Lotta, Luca A ^d   Kuusisto, Johanna ^c   Boren, Jan ^e   Blüher, Matthias ^f   Wareham, Nicholas J ^d   Ferrannini, Ele ^g   Groop, Per Henrik ^h,i,j   Laakso, Markku ^c   Langenberg, Claudia ^d   Smith, Ulf ^e  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^h FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

more..

Author keywords

albuminuria; CVD; insulin resistance; mannose; metabolomics; T2D

Indexed keywords

1,5 ANHYDROSORBITOL; GLUCOSE; HEMOGLOBIN A1C; LYSOPHOSPHOLIPID; MANNOSE; PHOSPHOLIPID; PLASMALOGEN; BIOLOGICAL MARKER;

BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; DIABETIC COMPLICATION; DIABETIC NEPHROPATHY; HEART FAILURE; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LETTER; METABOLIC SYNDROME X; METABOLITE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; AGED; ALBUMINURIA; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ALBUMINURIA; BIOMARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MANNOSE; MIDDLE AGED;

EID: 85026260651     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2017.07.006     Document Type: Letter

References (9)

1. Ekstrand, A.V., Groop, P.H., Grönhagen-Riska, C., Nephrol. Dial. Transplant. 13 (1998), 3079–3083.
2. Groop, L., Ekstrand, A., Forsblom, C., Widén, E., Groop, P.H., Teppo, A.M., Eriksson, J., Diabetologia 36 (1993), 642–647.
3. Hsu, C.C., Chang, H.Y., Huang, M.C., Hwang, S.J., Yang, Y.C., Tai, T.Y., Yang, H.J., Chang, C.T., Chang, C.J., Li, Y.S., et al. Diabetes Care 34 (2011), 982–987.
4. Lee, S., Zhang, C., Kilicarslan, M., Piening, B.D., Bjornson, E., Hallström, B.M., Groen, A.K., Ferrannini, E., Laakso, M., Snyder, M., et al. Cell Metab. 24 (2016), 172–184.
5. Lotta, L.A., Gulati, P., Day, F.R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K.J., Eicher, J.D., Sharp, S.J., Luan, J., et al. EPIC-InterAct Consortium, Cambridge FPLD1 Consortium. Nat. Genet. 49 (2017), 17–26.
6. Matsuda, M., DeFronzo, R.A., Diabetes Care 22 (1999), 1462–1470.
7. Scott, R.A., Fall, T., Pasko, D., Barker, A., Sharp, S.J., Arriola, L., Balkau, B., Barricarte, A., Barroso, I., Boeing, H., et al. RISC Study Group, EPIC-InterAct Consortium. Diabetes 63 (2014), 4378–4387.
8. Solini, A., Manca, M.L., Penno, G., Pugliese, G., Cobb, J.E., Ferrannini, E., J. Clin. Endocrinol. Metab. 101 (2016), 696–704.
9. Stancáková, A., Javorský, M., Kuulasmaa, T., Haffner, S.M., Kuusisto, J., Laakso, M., Diabetes 58 (2009), 1212–1221.